Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00441350
Status:
COMPLETED
Last Update Posted:
2021-07-28
First Post:
2007-02-27
Brief Title:
OlmesartanHCTZ 40125 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
Sponsor:
Menarini Group
Organization:
Menarini Group
Organization Data
Organization:
Menarini Group
Class:
INDUSTRY
Study ID:
CS866CM-B-E303
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Menarini Group
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Daiichi Sankyo Europe GmbH a Daiichi Sankyo Company | INDUSTRY |